1. National Institute for Health and Care Excellence. Interim process and methods of the Highly Specialised Technologies programme (updated to reflect 2017 changes). NICE; 2017.
https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance
. Accessed 13 Jun 2018.
2. National Institute for Health and Care Excellence. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency. Highly specialised technologies guidance [HST7]. NICE; 2018.
https://www.nice.org.uk/guidance/hst7
. Accessed 13 Jun 2018.
3. Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase–deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.
4. Hershfield M. Adenosine deaminase deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews®. Seattle: University of Washington; 2006 (Internet; updated 2017 Mar 16).
5. Adams SP, Wilson M, Harb E, Fairbanks L, Xu-Bayford J, Brown L, et al. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: segregation of genotypes with specific ethnicities. Clin Immunol. 2015;161(2):174–9.